The global GMP protein (E. coli) contract manufacturing market is estimated to be valued at US$ 685.8 Mn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2023 to 2030. GMP or "good manufacturing practices" protein derived from E. coli are being widely used for developing biologic drugs owing to its advantages such as high yield, stability and cost-effectiveness. The...